Literature DB >> 11257388

Mucosal immunity in the lung and upper airway.

J M Kyd1, A R Foxwell, A W Cripps.   

Abstract

The mucosal surfaces of the lungs and upper airways are common sites for infection. Extensive studies of the mechanisms associated with immune responses in the respiratory tract have found that understanding the system is challenging and involves many complex interactions to prevent and eliminate infection. Immune protection against diseases transmitted through the respiratory tract requires an understanding of the important aspects associated with beneficial, detrimental or ineffective immune responses. Two critical aspects of an immune response against a pathogen are that of the inductive stage, either induced by vaccination or primary infection, and the effector stage, the ability to recognise, respond to and eliminate the infection without detriment to the host. An immunisation strategy must not only have a measure of the induced antigen specific response, but this response must also be protective.

Entities:  

Mesh:

Year:  2001        PMID: 11257388     DOI: 10.1016/s0264-410x(00)00484-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Evaluation of a temperature-restricted, mucosal tuberculosis vaccine in guinea pigs.

Authors:  Tuhina Gupta; Monica LaGatta; Shelly Helms; Rebecca L Pavlicek; Simon O Owino; Kaori Sakamoto; Tamas Nagy; Stephen B Harvey; Mark Papania; Stephanie Ledden; Kevin T Schultz; Candace McCombs; Frederick D Quinn; Russell K Karls
Journal:  Tuberculosis (Edinb)       Date:  2018-10-19       Impact factor: 3.131

2.  Considerations for use of acupuncture as supplemental therapy for patients with allergic asthma.

Authors:  Yong-Qing Yang; Han-Ping Chen; Yu Wang; Lei-Miao Yin; Yu-Dong Xu; Jun Ran
Journal:  Clin Rev Allergy Immunol       Date:  2013-06       Impact factor: 8.667

3.  Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.

Authors:  Anja Krause; Wen Zhu Whu; Yaqin Xu; Ju Joh; Ronald G Crystal; Stefan Worgall
Journal:  Vaccine       Date:  2011-01-06       Impact factor: 3.641

4.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 5.  Chitosan-Based Nanoparticles Against Viral Infections.

Authors:  Homa Boroumand; Fereshteh Badie; Samaneh Mazaheri; Zeynab Sadat Seyedi; Javid Sadri Nahand; Majid Nejati; Hossein Bannazadeh Baghi; Mohammad Abbasi-Kolli; Bita Badehnoosh; Maryam Ghandali; Michael R Hamblin; Hamed Mirzaei
Journal:  Front Cell Infect Microbiol       Date:  2021-03-17       Impact factor: 5.293

6.  Sex-Specific Differences in Resolution of Airway Inflammation in Fat-1 Transgenic Mice Following Repetitive Agricultural Dust Exposure.

Authors:  Arzu Ulu; Jalene V Velazquez; Abigail Burr; Stefanie N Sveiven; Jun Yang; Carissa Bravo; Bruce D Hammock; Tara M Nordgren
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

Review 7.  A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.

Authors:  Shivani Singh; Noemi Alejandra Saavedra-Avila; Sangeeta Tiwari; Steven A Porcelli
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

8.  Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.

Authors:  Wu Li; Guangcun Deng; Min Li; Xiaoming Liu; Yujiong Wang
Journal:  Tuberc Res Treat       Date:  2012-11-01

9.  A multi-antigenic adenoviral-vectored vaccine improves BCG-induced protection of goats against pulmonary tuberculosis infection and prevents disease progression.

Authors:  Bernat Pérez de Val; Enric Vidal; Bernardo Villarreal-Ramos; Sarah C Gilbert; Anna Andaluz; Xavier Moll; Maite Martín; Miquel Nofrarías; Helen McShane; H Martin Vordermeier; Mariano Domingo
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

10.  PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium.

Authors:  Maytal Bivas-Benita; Stefan Romeijn; Hans E Junginger; Gerrit Borchard
Journal:  Eur J Pharm Biopharm       Date:  2004-07       Impact factor: 5.571

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.